you are here: HomeNewsSiiNews
sii
Jump to
35 Results Found
  • Urgently trying to work with AstraZeneca, SII, Indian govt to restart COVID-19 vaccine shipments: WHO Official Jun 19, 2021 10:37 AM IST

    Urgently trying to work with AstraZeneca, SII, Indian govt to restart COVID-19 vaccine shipments: WHO Official

    “We have a huge number of countries that have had to suspend rollout of their second doses of vaccines," Bruce Aylward, Senior Advisor to World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, said on Friday at a press briefing.

  • COVID-19: As vaccine shortage bites, Centre unlikely to take over procurement completely May 25, 2021 05:52 PM IST

    COVID-19: As vaccine shortage bites, Centre unlikely to take over procurement completely

    With their procurement tenders getting tepid response from global pharma majors, more states now want the Centre to once again take over as the sole procurer of vaccines. The Centre is unlikely to do so even as a supply-side shortage is expected, at least for the next three months

  • Exclusive | Government has not restricted vaccine makers and will not ban commercial exports, say officials May 19, 2021 02:26 PM IST

    Exclusive | Government has not restricted vaccine makers and will not ban commercial exports, say officials

    As the debate on allowing vaccine exports in the face of local shortage gains momentum, senior officials across key ministries say companies are free to honour their contractual obligations and sell abroad if they have enough doses

  • When to get the second dose of COVID-19 vaccine? Read on to find out May 18, 2021 04:32 PM IST

    When to get the second dose of COVID-19 vaccine? Read on to find out

    The Central government, last week, increased the gap between Covishield vaccine doses to 12-16 weeks.

  • Serum Institute of India CEO Adar Poonawala hits back at critics: Key Highlights of The Times interview May 02, 2021 09:45 AM IST

    Serum Institute of India CEO Adar Poonawala hits back at critics: Key Highlights of The Times interview

    Rejecting the charges of profiteering from the vaccine, Serum Institute of India CEO Adar Poonawala said that it is “totally incorrect” and added that Covishield will still be “the most affordable vaccine on the planet” even at a higher price. "

  • Nepal requests India to fast-track shipment of 10 lakh Covishield doses already paid for Apr 27, 2021 01:10 PM IST

    Nepal requests India to fast-track shipment of 10 lakh Covishield doses already paid for

    As a deadly second wave of COVID-19 continues, Nepal has also requested ventilators, oxygen cylinders and medical supplies from India. Though Nepal has approved a Chinese vaccine, it is not recognised by the WHO and there are concerns over its safety and efficacy.

  • COVID-19 Vaccine | Serum Institute issues clarification on Covishield pricing, says govt procurement is at 'far lower price' Apr 24, 2021 04:18 PM IST

    COVID-19 Vaccine | Serum Institute issues clarification on Covishield pricing, says govt procurement is at 'far lower price'

    "Covishield is the most affordable COVID-19 vaccine available in the market today. The initial prices were kept very low globally as it was based on advance funding given by those countries for at-risk vaccine manufacturing," Serum India said in a statement.

  • Help increase COVID-19 vaccine production, lift embargo on raw materials, Adar Poonawalla asks US President Biden Apr 16, 2021 02:34 PM IST

    Help increase COVID-19 vaccine production, lift embargo on raw materials, Adar Poonawalla asks US President Biden

    "I humbly request you to lift the embargo of raw material exports out of the U.S. so that vaccine production can ramp up. Your administration has the details," Poonawalla tweeted.

  • India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output Apr 07, 2021 07:19 PM IST

    India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output

    About 90 percent of the 86 million doses India has administered since mid-January have come from the Serum Institute of India, with the rest accounted for by a domestic vaccine developed by Bharat Biotech, which is also struggling to boost output.

  • COVID-19: Will prioritise India's vaccine needs for next few months, says SII CEO Adar Poonawalla Apr 06, 2021 06:36 PM IST

    COVID-19: Will prioritise India's vaccine needs for next few months, says SII CEO Adar Poonawalla

    Adar Poonawalla said that the Serum Institute of India has already delivered over 100 million doses to the government and is currently producing 65-70 million doses per month.

  • COVID-19 update | India extends shelf life of AstraZeneca vaccine to 9 months Mar 30, 2021 10:40 PM IST

    COVID-19 update | India extends shelf life of AstraZeneca vaccine to 9 months

    The approval, given to a licensed version of the drug made by the Serum Institute of India (SII) and exported to dozens of countries, could help health authorities minimise vaccine wastage and better plan their inoculation programmes.

  • COVID-19 | Vaccine exports to UK to be temporarily halted, says Adar Poonawalla Mar 18, 2021 10:15 PM IST

    COVID-19 | Vaccine exports to UK to be temporarily halted, says Adar Poonawalla

    The second batch of five million doses that SII is due to export to the UK will only be delivered once it is green-lighted by the Indian government.

  • India to get 97.2 million doses of COVID-19 vaccine from COVAX in first half of 2021 Feb 03, 2021 10:50 PM IST

    India to get 97.2 million doses of COVID-19 vaccine from COVAX in first half of 2021

    COVAX will be getting 240 million doses of AstraZeneca-Oxford University COVID-19 vaccine from SII and 96 million doses from AstraZeneca under the advance purchase agreement between Gavi and the vaccine makers. SII has agreed to supply COVID-19 vaccine at $3 per dose.

  • 1,000 doses of Covishield vaccine found 'frozen' in Assam, probe ordered Jan 19, 2021 10:21 PM IST

    1,000 doses of Covishield vaccine found 'frozen' in Assam, probe ordered

    The 100 vials at SMCH were allegedly stored at sub-zero temperature, which led to the freezing of the vaccine doses.

  • COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla Jan 18, 2021 09:13 AM IST

    COVID-19 vaccine export may start in 2 weeks, says Serum Institute CEO Adar Poonawalla

    Serum Institute's Chief Executive Officer Adar Poonawalla said that exports of the COVID-19 vaccine doses will start only after local requirements are fully met.

  • SII's Adar Poonawalla and Bharat Biotech's Krishna Ella set aside differences, say saving lives from COVID-19 is more important Jan 05, 2021 03:22 PM IST

    SII's Adar Poonawalla and Bharat Biotech's Krishna Ella set aside differences, say saving lives from COVID-19 is more important

    "We are fully aware of the importance of vaccines for people and countries alike, we hereby communicate our joint pledge to provide global access for our COVID-19 vaccines," they said.

  • COVID-19 vaccine | Expert panel to take up Pfizer, SII's emergency use authorisation applications soon Dec 22, 2020 05:22 PM IST

    COVID-19 vaccine | Expert panel to take up Pfizer, SII's emergency use authorisation applications soon

    Pfizer was the first to apply for the EUA in India on December 5. However, it sought more time from the Subject Expert Committee (SEC) as its experts were busy and could not present their case on December 9.

  • Serum Institute 'hopeful' of EUA by December-end, India vaccination drive could begin from January, says Adar Poonawalla Dec 12, 2020 01:08 PM IST

    Serum Institute 'hopeful' of EUA by December-end, India vaccination drive could begin from January, says Adar Poonawalla

    “By September-October 2021 hopefully there will be enough vaccines for everyone and normal life can return,” Adar Poonawalla said.

  • COVID-19 vaccine | After Pfizer, SII, Bharat Biotech seeks emergency use authorisation for its Covaxin Dec 07, 2020 10:08 PM IST

    COVID-19 vaccine | After Pfizer, SII, Bharat Biotech seeks emergency use authorisation for its Covaxin

    Bharat Biotech's vaccine candidate was in the news recently after Haryana minister Anil Vij, who had volunteered for the trial and was administered a dose, had tested positive for COVID-19.

  • India will not have to wait too long for COVID-19 vaccine, says PM Narendra Modi Dec 07, 2020 05:29 PM IST

    India will not have to wait too long for COVID-19 vaccine, says PM Narendra Modi

    During an all-party meeting on December 4, Prime Minister Narendra Modi had said the government is forming a comprehensive vaccination strategy, and had indicated that a vaccine might be available in the coming few weeks.

  • UK is getting Pfizer's COVID-19 vaccine next week, but India will have to wait till April for Covishield Dec 03, 2020 09:49 AM IST

    UK is getting Pfizer's COVID-19 vaccine next week, but India will have to wait till April for Covishield

    Serum Institute's COVID-19 vaccine supply to private companies and in the open market will start only after orders from the government are met.

  • COVID-19 update | DCGI finds no link between vaccine shot and 'adverse' reaction in Chennai volunteer during trial: Report Dec 02, 2020 10:12 PM IST

    COVID-19 update | DCGI finds no link between vaccine shot and 'adverse' reaction in Chennai volunteer during trial: Report

    ICMR Director General Dr Balram Bhargava had on Tuesday said adverse events do occur with drugs or vaccines or any other health intervention.

  • UK approves Pfizer's COVID-19 vaccine: When will it come to India and all other questions answered Dec 02, 2020 06:20 PM IST

    UK approves Pfizer's COVID-19 vaccine: When will it come to India and all other questions answered

    Pfizer and BioNTech said on December 2 the COVID-19 vaccine will be rolled out for use from next week. Here's everything you need to know about this vaccine candidate and more

  • COVID-19 vaccine | SII rejects claims of Covishield's adverse effect, threatens to seek damages in excess of Rs 100 crore Nov 29, 2020 08:23 PM IST

    COVID-19 vaccine | SII rejects claims of Covishield's adverse effect, threatens to seek damages in excess of Rs 100 crore

    The volunteer is falsely laying the blame for his medical problems on the trial of COVID-19 vaccine Covishield, said Serum Institute of India

  • COVID-19 vaccine | Participant of Covishield trial sends legal notice to SII, seeks Rs 5 crore compensation Nov 28, 2020 02:40 PM IST

    COVID-19 vaccine | Participant of Covishield trial sends legal notice to SII, seeks Rs 5 crore compensation

    The participant received the vaccine on October 1 and on October 11, he started experiencing severe headaches and was not able to respond to questions, said the notice to Serum Institute of India

Sections